Cellectis Receives FDA RMAT Designation for Leukemia CAR-T Candidate Lasme-cel
Cellectis announced that its CD22-targeting allogeneic CAR-T therapy, lasme-cel, received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA for a severe form of leukemia. The RMAT status is expected to accelerate regulatory development and could provide benefits such as priority review or accelerated approval.
Tickers: $CLLS
Topics: biotech car-t therapy leukemia treatment